SCHEMBL719608

SCHEMBL719608

Cc1c(C(=O)C2CCCCC2)sc2cnccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
CASP1 P29466 1/20 0.44
HTT P42858 1/20 0.44
CASP7 P55210 1/20 0.44
NCOA1 Q15788 1/20 0.44
HSD17B10 Q99714 1/20 0.44
RCE1 Q9Y256 1/20 0.44
NCOA3 Q9Y6Q9 1/20 0.44
ESR1 P03372 1/20 0.40
ABL1 P00519 1/20 0.36
MAPT P10636 4/20 0.36
TP53 P04637 2/20 0.36
CYP2C19 P33261 1/20 0.36
CDK2 P24941 2/20 0.35
RPS6KB1 P23443 1/20 0.35
MAPKAPK2 P49137 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718685 0.90 ESR1 (0.40) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL717434 0.79 PRNP (0.51) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL3925107 0.77 ALDH1A1 (0.52) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL724156 0.74 LIMK1 (0.45) ALDH1A1GAAHPGDHTTESR1
SCHEMBL718690 0.74 IKBKB (0.45) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1813746 0.73 ALDH1A1 (0.72) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL717339 0.71 ALDH1A1 (0.53) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL4011666 0.68 HTT (0.49) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL4011672 0.68 HTT (0.49) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL23963781 0.67 KDM4E (0.43) KDM4EALDH1A1GLAGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP KDM4E 1907/4885ALDH1A1 504/4885GLA 710/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP KDM4E 1907/4885ALDH1A1 504/4885GLA 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.